Unlocking Epstein-Barr Virus (EBV): Tests, Symptoms, & Diagnosis
Epstein-Barr Virus (EBV), a member of the Herpesviridae family, is one of the most common human viruses. It is the primary cause of infectious mononucleosis and is linked to various conditions, including cancers (e.g., Burkitt’s lymphoma, nasopharyngeal carcinoma) and autoimmune diseases. Early recognition and appropriate testing are critical for diagnosis and management.

1. What is EBV?
Virus Type: Double-stranded DNA virus.
Transmission:
Spread through saliva (“kissing disease”), blood, organ transplantation, or sharing utensils.
At-Risk Populations:
Adolescents and young adults for infectious mononucleosis.
Immunocompromised individuals for reactivation or malignancies.
2. Symptoms of EBV Infection
A. Primary Infection (Infectious Mononucleosis)
Classic Triad:
Fever.
Sore throat.
Lymphadenopathy (swollen lymph nodes).
Other Symptoms:
Fatigue.
Splenomegaly (enlarged spleen).
Hepatomegaly (enlarged liver).
Skin rash (may occur after taking antibiotics like amoxicillin).
B. Reactivation
Often asymptomatic but may cause:
Persistent fatigue.
Fever and malaise.
Complications in immunocompromised patients (e.g., post-transplant lymphoproliferative disorder).
C. Chronic EBV
Rare, long-lasting symptoms such as fatigue, low-grade fever, and lymphadenopathy.
3. Why is EBV Testing Important?
Confirmation of Diagnosis:
Helps differentiate EBV from other conditions like cytomegalovirus (CMV) or strep throat.
Disease Monitoring:
Tracks reactivation in high-risk patients (e.g., transplant recipients).
Detects EBV-Associated Cancers:
Confirms EBV’s role in malignancies like Hodgkin’s lymphoma.
4. Diagnostic Tests for EBV
A. Serological Testing
Heterophile Antibody Test (Monospot Test)

Purpose:
Detects heterophile antibodies in infectious mononucleosis.
Timing:
Best used 2–4 weeks after symptom onset.
Limitations:
False negatives in early infection or young children.
EBV-Specific Antibodies

Viral Capsid Antigen (VCA):
VCA IgM: Indicates acute infection.
VCA IgG: Indicates past infection or immunity.
Early Antigen (EA):
Appears during active infection; disappears after recovery.
EBV Nuclear Antigen (EBNA):
Indicates past or latent infection; appears 6–8 weeks after infection.
B. Molecular Testing
Polymerase Chain Reaction (PCR)

What It Detects:
EBV DNA in blood or tissues.
Applications:
Useful in immunocompromised patients to detect reactivation.
Monitors viral load in EBV-associated diseases.
In Situ Hybridization

Detects EBV-encoded RNA (EBER) in tissue biopsies, confirming EBV involvement in malignancies.
C. Complete Blood Count (CBC)
Findings:
Lymphocytosis (elevated lymphocyte count).
Atypical lymphocytes.
D. Liver Function Tests (LFTs)
Elevated liver enzymes (ALT, AST) indicate liver involvement in mononucleosis.
5. Interpreting Serology Results
Antibody Positive Result Clinical Interpretation
VCA IgM Recent infection Primary acute EBV infection.
VCA IgG Past or active infection Confirms past exposure or current infection.
EA IgG Active infection Indicates acute or reactivated infection.
EBNA IgG Past infection Rules out acute infection if EBNA is positive.
6. EBV-Associated Conditions
Cancers:
Burkitt’s lymphoma.
Hodgkin’s lymphoma.
Nasopharyngeal carcinoma.
Post-transplant lymphoproliferative disorder (PTLD).
Autoimmune Diseases:
Multiple sclerosis.
Systemic lupus erythematosus (SLE).
Chronic Fatigue Syndrome (CFS):
Suspected link with chronic EBV infection.
7. Limitations of EBV Testing
False Positives:
Cross-reactivity with other herpesviruses.
Heterophile Test Sensitivity:
Low sensitivity in children and early stages of infection.
Latency:
Positive EBNA and VCA IgG do not confirm active infection.
8. Complementary Tests
Imaging Studies:
CT or ultrasound to evaluate splenomegaly or lymphadenopathy.
Tissue Biopsy:
Confirms EBV’s role in lymphoproliferative disorders or malignancies.
9. Treatment and Management
Supportive Care:
Rest, hydration, and symptomatic relief with antipyretics and analgesics.
Avoiding Physical Activity:
Prevents splenic rupture in cases of splenomegaly.
Antivirals:
Limited use; reserved for severe or chronic cases.
Immune Modulation:
For post-transplant lymphoproliferative disorder.
10. Conclusion
EBV testing is crucial for diagnosing infectious mononucleosis, monitoring reactivation, and identifying EBV-associated conditions. Combining serological and molecular testing ensures accurate diagnosis and optimal patient care. Early detection and management are key to reducing complications and improving outcomes.

свернуть